Effectiveness of ultrasound-guided subacromial bursa injection of betamethasone combined with hyaluronate in treatment of subacromial bursitis
10.3877/cma.j.issn.1672-6448.2015.06.015
- VernacularTitle:超声引导下复方倍他米松联合玻璃酸钠注射治疗肩峰下滑囊炎的临床研究
- Author:
Xueqing, CHENG
;
Man, LU
;
Fanding, HE
;
Xuanyan, GUO
- Publication Type:Journal Article
- Keywords:
Bursitis;
Ultrasonography,interventional;
Hyaluronate;
Betamethasone
- From:
Chinese Journal of Medical Ultrasound (Electronic Edition)
2015;(6):488-492
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the effectiveness of ultrasound-guided (US-guided) subacromial bursa injection of betamethasone combined with hyaluronate for treatment of subacromial bursitis.MethodsA total of 72 patients who were diagnosed as subacromial bursitis by ultrasound and then decided to performed US-guided subacromial bursa injection were randomly divided into two groups. The study group was treated with compound betamethasone suspension followed by sodium hyaluronate, and the control group was treated only with compound betamethasone suspension. Visual analogue score (VAS) and the shoulder active abduction range of motion (AAROM) score were observed before treatment, 1 week and 4 weeks post-treatment during 1 month's followed-up.ResultsThere were signifi cantly decreased in VAS score and increased in AAROM score at 1 week and 4 weeks post treatment for both groups (bothP<0.05). There was no difference of both VAS score and AAROM score between the two groups at 1 week post treatment (bothP>0.05). But at 4 weeks post treatment, the VAS score of the study group was signifi cantly lower than that of the control group (2.08±1.95vs 3.14±2.0,P<0.05), while the AAROM score of the study group was signifi cantly higher than that of the control group (7.12±2.10vs 6.11±1.93,P<0.05). ConclusionsUltrasound-guided subacromial bursa injection of betamethasone combined with hyaluronate is effective in treating subacromial bursitis. It produces better pain and active abduction functional improvement than betamethasone at a short-term follow-up.
